CO5630023A2 - Fenil quinolinas y su uso como agentes estrogenicos - Google Patents
Fenil quinolinas y su uso como agentes estrogenicosInfo
- Publication number
- CO5630023A2 CO5630023A2 CO05114679A CO05114679A CO5630023A2 CO 5630023 A2 CO5630023 A2 CO 5630023A2 CO 05114679 A CO05114679 A CO 05114679A CO 05114679 A CO05114679 A CO 05114679A CO 5630023 A2 CO5630023 A2 CO 5630023A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- halogen
- alkenyl
- alkoxy
- cho
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
1.- Un compuesto de fórmula: en el cual:A y AAND#39 son cada uno, en forma independiente, OH u OP;P es alquilo, alquenilo, bencilo, acilo, aroilo, alcoxicarbonilo, sulfonilo o fosforilo;R1 y R2 son cada uno, en forma independiente, H, halógeno, alquilo C1-C6, alquenilo C2-C7, o alcoxi C1-C6;R3 es H, halógeno, o alquilo C1-C6;R4 es H, halógeno, alquilo C1-C6, alquenilo C2-C7, alquinilo C2-C7, cicloalquilo C3-C7, alcoxi C1-C6, -CN, -CHO, acilo, o heteroarilo;R5 y R6 son cada uno, en forma independiente, H, halógeno, alquilo C1-C6, alquenilo C2-C7, alquinilo C2-C7, cicloalquilo C3-C7, alcoxi C1-C6, -CN, -CHO, acilo, fenilo, arilo o heteroarilo, siempre que por lo menos uno de R4, R5 y R6 sea halógeno, alquilo C1-C6, alquenilo C2-C7, alquinilo C2-C7, cicloalquilo C3-C7, alcoxi C1-C6, -CN, -CHO, acilo, fenilo, arilo o heteroarilo;en el cual los restos alquilo o alquenilo de R4, R5 o R6 pueden estar sustituidos en forma opcional con halógeno, OH, -CN, trifluroalquilo, trifluoroalcoxi, -NO2, o fenilo;en el cual el resto alquinilo de R4, R5 o R6 puede estar sustituido en forma opcional con halógeno, -CN, -CHO, acilo, trifluroalquilo, trialquilsililo, o fenilo sustituido en forma opcional;en el cual el resto fenilo de R5 o R6 puede ser en forma opcional mono-, di-, o trisustituido con halógeno, alquilo C1-C6, alquenilo C2-C7, OH, alcoxi C1-C6, -CN, -CHO, -NO2, amino, alquil C1-C6amino, di-alquilamino (C1-C6), tiol, o alquiltio C1-C6;siempre que cuando cada uno de R4, R5 y R6 son H, alquilo C1-C6, alquenilo C2-C7, o alcoxi C1-C6, entonces por lo menos uno de R1 y R2 es halógeno, alquilo C1-C6, alquenilo C2-C7, o alcoxi C1-C6;siempre que por lo menos uno de R4 y R6 sea distinto de H;o uno de sus N-óxidos o una de sus sales aceptables desde el punto de vista farmacéutico o uno de sus profármacos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47143603P | 2003-05-16 | 2003-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5630023A2 true CO5630023A2 (es) | 2006-04-28 |
Family
ID=33476843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05114679A CO5630023A2 (es) | 2003-05-16 | 2005-11-10 | Fenil quinolinas y su uso como agentes estrogenicos |
Country Status (19)
Country | Link |
---|---|
US (2) | US7084276B2 (es) |
EP (1) | EP1628961A1 (es) |
JP (1) | JP2007504281A (es) |
KR (1) | KR20060013405A (es) |
CN (1) | CN1823046A (es) |
AR (1) | AR044349A1 (es) |
AU (1) | AU2004241239A1 (es) |
BR (1) | BRPI0410418A (es) |
CA (1) | CA2525292A1 (es) |
CL (1) | CL2004000985A1 (es) |
CO (1) | CO5630023A2 (es) |
CR (1) | CR8080A (es) |
EC (1) | ECSP056167A (es) |
MX (1) | MXPA05012248A (es) |
NO (1) | NO20055135L (es) |
RU (1) | RU2005139393A (es) |
TW (1) | TW200510319A (es) |
WO (1) | WO2004103973A1 (es) |
ZA (1) | ZA200509248B (es) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080221029A1 (en) * | 2002-10-31 | 2008-09-11 | Regents Of The University Of Colorado | Methods for treatment of thiol-containing compound deficient conditions |
CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
DE202004021953U1 (de) | 2003-09-12 | 2013-06-19 | Vessix Vascular, Inc. | Auswählbare exzentrische Remodellierung und/oder Ablation von atherosklerotischem Material |
BRPI0512783A (pt) * | 2004-07-01 | 2008-04-08 | Wyeth Corp | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto |
EP1789420A2 (en) | 2004-09-07 | 2007-05-30 | Wyeth, A Corporation of the State of Delaware | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS |
US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
AR051844A1 (es) * | 2004-12-17 | 2007-02-14 | Wyeth Corp | Uso de agonistas beta de estrogenos en desordenes o enfermedades cognitivas |
PE20061092A1 (es) * | 2005-02-16 | 2006-12-05 | Wyeth Corp | COMPUESTOS HETEROCICLICOS COMO AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO |
WO2007092820A2 (en) * | 2006-02-03 | 2007-08-16 | Lazarus Effect, Inc. | Methods and devices for restoring blood flow within blocked vasculature |
US8019435B2 (en) | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
AU2007310986B2 (en) | 2006-10-18 | 2013-07-04 | Boston Scientific Scimed, Inc. | Inducing desirable temperature effects on body tissue |
EP2076194B1 (en) | 2006-10-18 | 2013-04-24 | Vessix Vascular, Inc. | System for inducing desirable temperature effects on body tissue |
JP5312337B2 (ja) | 2006-10-18 | 2013-10-09 | べシックス・バスキュラー・インコーポレイテッド | 標的組織の選択的な処置のための調節されたrfエネルギーおよび電気的な組織の特徴付け |
US9078888B2 (en) | 2007-01-22 | 2015-07-14 | Gtx, Inc. | Nuclear receptor binding agents |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
TW200838509A (en) * | 2007-01-31 | 2008-10-01 | Wyeth Corp | Use of ERβ selective ligands for treating acute lung injuries |
EP2355737B1 (en) | 2008-11-17 | 2021-08-11 | Boston Scientific Scimed, Inc. | Selective accumulation of energy without knowledge of tissue topography |
KR101101977B1 (ko) * | 2009-04-09 | 2012-01-02 | (주)에스메디 | 2-아릴나프탈렌, 2-아릴퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
EA201201052A1 (ru) | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
AU2011238925B2 (en) | 2010-04-09 | 2016-06-16 | Vessix Vascular, Inc. | Power generating and control apparatus for the treatment of tissue |
US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
US8473067B2 (en) | 2010-06-11 | 2013-06-25 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
CN103200820B (zh) | 2010-10-08 | 2016-04-06 | 尼瓦利斯治疗公司 | 作为s-亚硝基谷胱甘肽还原酶抑制剂的取代喹啉化合物 |
US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
KR20140053811A (ko) * | 2010-10-29 | 2014-05-08 | 클리노 가부시끼가이샤 | 타우 이미징 프로브 |
US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
RU2462455C2 (ru) * | 2010-12-01 | 2012-09-27 | Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) | Способ получения гидроксипроизводных стирилхинолинов |
US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
WO2012083165A1 (en) * | 2010-12-16 | 2012-06-21 | N30 Pharmaceuticals, Llc | Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors |
US9220561B2 (en) | 2011-01-19 | 2015-12-29 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
AU2012283908B2 (en) | 2011-07-20 | 2017-02-16 | Boston Scientific Scimed, Inc. | Percutaneous devices and methods to visualize, target and ablate nerves |
EP2734264B1 (en) | 2011-07-22 | 2018-11-21 | Boston Scientific Scimed, Inc. | Nerve modulation system with a nerve modulation element positionable in a helical guide |
JP5860960B2 (ja) | 2011-07-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キノリン類及び医薬としてのそれらの使用 |
EP2741609A4 (en) | 2011-08-12 | 2015-04-08 | Salk Inst For Biological Studi | NEUROPROTECTIVE POLYPHENOLANALOGA |
WO2013055826A1 (en) | 2011-10-10 | 2013-04-18 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
US10085799B2 (en) | 2011-10-11 | 2018-10-02 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
US9162046B2 (en) | 2011-10-18 | 2015-10-20 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
WO2013059202A1 (en) | 2011-10-18 | 2013-04-25 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
CN108095821B (zh) | 2011-11-08 | 2021-05-25 | 波士顿科学西美德公司 | 孔部肾神经消融 |
EP2779929A1 (en) | 2011-11-15 | 2014-09-24 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
CA2861622C (en) | 2011-12-23 | 2020-10-27 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
WO2013101452A1 (en) | 2011-12-28 | 2013-07-04 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
WO2013169927A1 (en) | 2012-05-08 | 2013-11-14 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
CN104540465A (zh) | 2012-08-24 | 2015-04-22 | 波士顿科学西美德公司 | 带有含单独微孔隙区域的球囊的血管内导管 |
US9173696B2 (en) | 2012-09-17 | 2015-11-03 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
US10398464B2 (en) | 2012-09-21 | 2019-09-03 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
WO2014047454A2 (en) | 2012-09-21 | 2014-03-27 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
CN104869930B (zh) | 2012-10-10 | 2020-12-25 | 波士顿科学国际有限公司 | 肾神经调制装置和方法 |
US9693821B2 (en) | 2013-03-11 | 2017-07-04 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
WO2014149690A2 (en) | 2013-03-15 | 2014-09-25 | Boston Scientific Scimed, Inc. | Medical devices and methods for treatment of hypertension that utilize impedance compensation |
JP6220044B2 (ja) | 2013-03-15 | 2017-10-25 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 腎神経アブレーションのための医療用デバイス |
US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
CN103274999A (zh) * | 2013-06-13 | 2013-09-04 | 程杰 | 3-卤代喹啉衍生物和其制备方法 |
CN105473091B (zh) | 2013-06-21 | 2020-01-21 | 波士顿科学国际有限公司 | 具有可一起移动的电极支撑件的肾脏去神经球囊导管 |
US10022182B2 (en) | 2013-06-21 | 2018-07-17 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation having rotatable shafts |
US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
US9833283B2 (en) | 2013-07-01 | 2017-12-05 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
CN105377170A (zh) | 2013-07-11 | 2016-03-02 | 波士顿科学国际有限公司 | 具有可伸展电极组件的医疗装置 |
WO2015006480A1 (en) | 2013-07-11 | 2015-01-15 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation |
WO2015010074A1 (en) | 2013-07-19 | 2015-01-22 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
US10342609B2 (en) | 2013-07-22 | 2019-07-09 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
EP3024405A1 (en) | 2013-07-22 | 2016-06-01 | Boston Scientific Scimed, Inc. | Renal nerve ablation catheter having twist balloon |
EP4049605A1 (en) | 2013-08-22 | 2022-08-31 | Boston Scientific Scimed Inc. | Flexible circuit having improved adhesion to a renal nerve modulation balloon |
US9895194B2 (en) | 2013-09-04 | 2018-02-20 | Boston Scientific Scimed, Inc. | Radio frequency (RF) balloon catheter having flushing and cooling capability |
EP3043733A1 (en) | 2013-09-13 | 2016-07-20 | Boston Scientific Scimed, Inc. | Ablation balloon with vapor deposited cover layer |
US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
US9687166B2 (en) | 2013-10-14 | 2017-06-27 | Boston Scientific Scimed, Inc. | High resolution cardiac mapping electrode array catheter |
US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
CN105636537B (zh) | 2013-10-15 | 2018-08-17 | 波士顿科学国际有限公司 | 医疗器械球囊 |
CN105636538B (zh) | 2013-10-18 | 2019-01-15 | 波士顿科学国际有限公司 | 具有柔性导线的球囊导管及其使用和制造的相关方法 |
CN105658163B (zh) | 2013-10-25 | 2020-08-18 | 波士顿科学国际有限公司 | 去神经柔性电路中的嵌入式热电偶 |
JP6382989B2 (ja) | 2014-01-06 | 2018-08-29 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 耐引き裂き性フレキシブル回路アセンブリを備える医療デバイス |
JP6325121B2 (ja) | 2014-02-04 | 2018-05-16 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 双極電極上の温度センサの代替配置 |
US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
US10399946B2 (en) | 2015-09-10 | 2019-09-03 | Laurel Therapeutics Ltd. | Solid forms of an S-Nitrosoglutathione reductase inhibitor |
KR102577142B1 (ko) * | 2018-07-12 | 2023-09-12 | 일라이 릴리 앤드 캄파니 | 선택적 에스트로겐 수용체 분해제 |
CN109096185A (zh) * | 2018-09-18 | 2018-12-28 | 江西科技师范大学 | 一种4-溴-喹啉衍生物的合成方法 |
CN110357811A (zh) * | 2019-07-12 | 2019-10-22 | 南通大学 | 一种含喹啉骨架化合物及其制备方法和应用 |
CN116574054A (zh) * | 2023-05-15 | 2023-08-11 | 南京中医药大学 | 选择性雌激素受体下调剂化合物、制备方法及用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US5126351A (en) * | 1991-01-24 | 1992-06-30 | Glaxo Inc. | Antitumor compounds |
US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
AU7622000A (en) | 1999-10-01 | 2001-05-10 | Institute Of Molecular And Cell Biology | Compounds for the treatment of viral-mediated diseases |
AR030064A1 (es) | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
PT1401446E (pt) | 2001-05-22 | 2005-05-31 | Lilly Co Eli | Derivados de tetrahidroquinolina para a inibicao de doencas associadas com a privacao de estrogenio ou com uma resposta fisiologica aberrante ao estrogenio endogeno |
ATE321754T1 (de) | 2001-05-22 | 2006-04-15 | Lilly Co Eli | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
TWI306450B (en) * | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
US6774248B2 (en) | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
-
2004
- 2004-05-07 CL CL200400985A patent/CL2004000985A1/es unknown
- 2004-05-13 BR BRPI0410418-8A patent/BRPI0410418A/pt not_active IP Right Cessation
- 2004-05-13 US US10/846,216 patent/US7084276B2/en not_active Expired - Fee Related
- 2004-05-13 WO PCT/US2004/015142 patent/WO2004103973A1/en active Application Filing
- 2004-05-13 TW TW093113389A patent/TW200510319A/zh unknown
- 2004-05-13 KR KR1020057021886A patent/KR20060013405A/ko not_active Application Discontinuation
- 2004-05-13 CN CNA2004800201518A patent/CN1823046A/zh not_active Withdrawn
- 2004-05-13 RU RU2005139393/04A patent/RU2005139393A/ru not_active Application Discontinuation
- 2004-05-13 CA CA002525292A patent/CA2525292A1/en not_active Abandoned
- 2004-05-13 MX MXPA05012248A patent/MXPA05012248A/es active IP Right Grant
- 2004-05-13 EP EP04752218A patent/EP1628961A1/en not_active Withdrawn
- 2004-05-13 JP JP2006533069A patent/JP2007504281A/ja active Pending
- 2004-05-13 AU AU2004241239A patent/AU2004241239A1/en not_active Withdrawn
- 2004-05-14 AR ARP040101666A patent/AR044349A1/es not_active Application Discontinuation
-
2005
- 2005-11-02 NO NO20055135A patent/NO20055135L/no unknown
- 2005-11-08 CR CR8080A patent/CR8080A/es not_active Application Discontinuation
- 2005-11-10 CO CO05114679A patent/CO5630023A2/es not_active Application Discontinuation
- 2005-11-15 ZA ZA200509248A patent/ZA200509248B/en unknown
- 2005-11-16 EC EC2005006167A patent/ECSP056167A/es unknown
-
2006
- 2006-05-31 US US11/443,861 patent/US7632845B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2007504281A (ja) | 2007-03-01 |
WO2004103973A8 (en) | 2005-03-31 |
AR044349A1 (es) | 2005-09-07 |
NO20055135D0 (no) | 2005-11-02 |
US20050009784A1 (en) | 2005-01-13 |
CN1823046A (zh) | 2006-08-23 |
CA2525292A1 (en) | 2004-12-02 |
EP1628961A1 (en) | 2006-03-01 |
ZA200509248B (en) | 2008-04-30 |
US7632845B2 (en) | 2009-12-15 |
NO20055135L (no) | 2005-12-14 |
AU2004241239A1 (en) | 2004-12-02 |
ECSP056167A (es) | 2006-04-19 |
CL2004000985A1 (es) | 2005-01-14 |
CR8080A (es) | 2006-05-29 |
US7084276B2 (en) | 2006-08-01 |
TW200510319A (en) | 2005-03-16 |
WO2004103973A1 (en) | 2004-12-02 |
US20060217399A1 (en) | 2006-09-28 |
MXPA05012248A (es) | 2006-02-10 |
RU2005139393A (ru) | 2006-07-27 |
KR20060013405A (ko) | 2006-02-09 |
BRPI0410418A (pt) | 2006-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5630023A2 (es) | Fenil quinolinas y su uso como agentes estrogenicos | |
ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
AR063786A1 (es) | Derivados de 1,4 -benzotiepina-1,1 dioxido sustituidos con radicales bencilo, productos farmaceuticos que comprenden estos compuestos y su uso | |
AR039689A1 (es) | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso | |
AR055053A1 (es) | Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas. | |
AR041739A1 (es) | Compuestos derivados -3,4-dihidro-1h-pirimido[4,5-d]pirimidin-2-ona y con actividad antiproliferativa. | |
DK2258401T3 (da) | Folat-receptor targetede billeddannelsesmidler | |
CR7899A (es) | Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa | |
ECSP056127A (es) | Inhibidores de 3-quinasa de fosfatidil-inositol | |
PE20141702A1 (es) | Compuestos de carbamato y preparacion y uso de los mismos | |
CY1108738T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου | |
AR042273A1 (es) | Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen | |
PE20040688A1 (es) | Inhibidores de quinasas | |
ECSP055582A (es) | Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor | |
CY1107851T1 (el) | Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2 | |
CO5080735A1 (es) | Agonistas de prostaglandinas | |
ES2534055T3 (es) | Opioides de amina no fenólicos con sustituyentes de gran tamaño | |
DK1643984T3 (da) | Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler | |
NO20033584D0 (no) | Bredspektrede 2-(substituert-amino)-benzotiazolsulfonamid-hiv- proteaseinhibitorer | |
NO20060896L (no) | Alfa-aminoamidderivater nyttige som antiinflammatoriske midler | |
AR012092A1 (es) | Compuestos derivados de aril y heteroaril carboxamida, procedimiento para su preparacion, composicion farmaceutica que lo comprenden, y el uso de dichosderivados para la fabricacion de un medicamento. | |
ES2530815T3 (es) | Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas | |
AR047486A1 (es) | Derivados de indolizina1,2,3,6,7,8, substituida, inhibidores de los fgfs, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
AR029005A1 (es) | FORMULACION LíQUIDA ESTABLE SIN AGUA O CASI SIN AGUA DE BENCIMIDAZOLES SUSTITUIDOS, PROCESO PARA SU PREPARACIoN, USO DE ESTA FORMULACIoN, Y USO DE POLIETILENGLICOL Y UNA SAL DE SODIO O POTASIO DE UN INHIBIDOR DE H+, K+-ATP ASA | |
AR052663A1 (es) | Compuestos de oxima heterociclicos, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |